You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The company recently presented results from its Aurora assay for multi-cancer screening and plans to launch a $100 test for the US and Chinese markets.
At the AACR annual meeting, researchers shared detection rate data for multi-cancer screening tests from Grail and Thrive Earlier Detection.
The company released new data showing that Cologuard 2.0 can detect colorectal cancer with higher sensitivity than the current version of the test.
The team identified six independent DNA methylation blocks that could potentially help to predict the formation of central nervous system metastases in lung cancer.
Exact Sciences and the Mayo Clinic are working to develop a blood test for pancreatic cancer that might be able to diagnose patients with early-stage disease.
The company reported that its genome-wide methylation approach could detect 77 percent of stage II cancers in its ongoing case-control CCGA study.
The company presented new data on the performance of a multi-pronged liquid biopsy assay in detecting colorectal cancers across a range of clinical stages.
A team led by Walter and Eliza Hall Institute researchers found that ovarian tumors with complete BRCA1 methylation and silencing were more susceptible to treatment.
Using archived tumor samples from individuals with glioblastoma, researchers saw methylation variability at progression, along with potential prognostic hints.